Telomir Pharmaceuticals (NASDAQ: TELO) has announced the publication of peer-reviewed preclinical data in Advances in Redox Research demonstrating that Telomir-Zn, the company’s lead small-molecule therapeutic, delivers dose-dependent survival improvements and multiple therapeutic benefits in a Wilson’s disease model. The study showed that Telomir-Zn reduced oxidative stress, lowered hepatic copper burden, and improved liver function markers, supporting its biological activity in Wilson’s disease.
Wilson’s disease is a rare genetic disorder characterized by copper accumulation in the liver and brain, leading to progressive liver damage and neurological symptoms. Current treatments focus on chelation therapy or zinc supplementation to reduce copper absorption, but they often have limited efficacy and significant side effects. The preclinical findings suggest that Telomir-Zn may offer a novel approach by modulating intracellular metal homeostasis and redox balance.
The data expand the scientific validation of Telomir-Zn beyond its primary focus on triple-negative breast cancer (TNBC), for which the company is advancing toward Phase 1/2 clinical initiation. Telomir-Zn has previously demonstrated activity in preclinical models of TNBC by targeting epigenetic and metabolic mechanisms. The new findings in Wilson’s disease highlight the drug’s potential across multiple indications.
“These results further validate the broad therapeutic potential of Telomir-Zn,” said a company spokesperson. “The ability to improve survival and reduce key disease markers in a Wilson’s disease model underscores the drug’s mechanism of action in modulating metal homeostasis and oxidative stress.”
Telomir Pharmaceuticals is a preclinical-stage biotechnology company focused on developing small-molecule therapeutics that target fundamental mechanisms in cancer, aging, and degenerative diseases. Its lead program, Telomir-1 (Telomir-Zn), has shown activity in preclinical studies involving intracellular metal homeostasis, redox balance, epigenetically regulated gene expression, mitochondrial function, and genomic stability.
The full press release is available at https://ibn.fm/fOSNo. For more information about Telomir Pharmaceuticals, visit the company’s newsroom at https://ibn.fm/TELO.
